AnaptysBio (NASDAQ:ANAB) Issues Quarterly Earnings Results

AnaptysBio (NASDAQ:ANAB) released its quarterly earnings data on Thursday. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.84) by $1.95, FiscalAI reports. The business had revenue of $30.27 million during the quarter, compared to analyst estimates of $25.56 million. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%.

AnaptysBio Stock Performance

NASDAQ:ANAB traded down $1.00 during mid-day trading on Thursday, hitting $47.77. The stock had a trading volume of 262,896 shares, compared to its average volume of 660,430. AnaptysBio has a twelve month low of $21.93 and a twelve month high of $72.36. The company’s 50 day simple moving average is $50.17 and its 200 day simple moving average is $56.31. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of 8.90 and a beta of 0.70.

Insider Activity at AnaptysBio

In other AnaptysBio news, Director Hollings Renton sold 5,000 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $49.87, for a total value of $249,350.00. Following the transaction, the director directly owned 10,995 shares in the company, valued at $548,320.65. The trade was a 31.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 31.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ANAB shares. HC Wainwright restated a “buy” rating and set a $95.00 price objective on shares of AnaptysBio in a report on Tuesday, September 22nd. JPMorgan Chase & Co. lowered their target price on AnaptysBio from $70.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, September 30th. Wall Street Zen cut AnaptysBio from a “buy” rating to a “hold” rating in a research note on Sunday, October 4th. Scotiabank downgraded AnaptysBio to a “hold” rating and set a $70.00 price target for the company. in a report on Tuesday, August 25th. Finally, Wolfe Research restated an “outperform” rating and issued a $78.00 price target on shares of AnaptysBio in a report on Monday, August 31st. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, AnaptysBio currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.67.

AnaptysBio Company Profile

AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.